New Clinical Trial for Primary Liver Tumors

An exciting new clinical trial for primary liver tumors at North Shore-LIJ Health System combines Radio frequency Thermal Ablation (RFA) and a novel heat-activated liposomal chemotherapy formulation targeted to tumor.

RFA is becoming standard therapy for many inoperable patients with liver cancer. This trial is investigating targeting HCC tumors with a combination of RFA and an experimental drug, ThermoDox®. The clinical trial is a two arm randomized, blinded, Phase III study comparing RFA alone versus RFA plus ThermoDox®. If Radomized to the RFA plus ThermoDox® arm, of the study, the RFA will be combined with the local delivery of chemotherapy in one procedure. The drug is given intravenously during RFA and is deposited locally in and around the tumor. The hope is that this will minimize side effects, and make the chemotherapy more targeted.

Patients 18 years of age and older who have non resectable HCC (primary liver cancer) may be eligible for this study.  Candidates are screened with a medical history, physical examination, blood tests, EKG and imaging studies (CT/MRI; PET). These tests are repeated at various intervals during the study to monitor treatment effects.

If you would like to know more, or if you have a patient who might benefit from this procedure, please contact Karen Fehn, R.N., research coordinator, via phone 516-562-2933 or e-mail kfehn@nshs.edu. More information can be found at www.clinicaltrials.gov.

Last Update

January 29, 2010
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search All Services:
top